Akademik Veri Yönetim Sistemi
Pharmaceutical Biology, cilt.53, sa.2, ss.275-279, 2015 (SCI-Expanded)
© 2015 Informa Healthcare USA, Inc.Context: Crataegus species are widely used as herbal medicines for preventing cardiovascular diseases (CVDs). However, there are no studies on the effects of Crataegus monogyna Jacq. (Rosaceae) and C. davisii Browicz on thrombosis, which is an important mechanism in CVDs. Objective: The purpose of this study was to investigate the antithrombotic effects of ethanol extracts of Crataegus monogyna (CMEx) and C. davisii (CDEx) leaves by using the carrageenan-induced tail thrombosis model. Materials and methods: The hind paw of each mouse was injected with 1% Type I carrageenan to induce thrombosis. CMEx was tested at the doses of 100, 200, and 300mg/kg and CDEx at the dose of 50, 100, 200, and 300mg/kg in comparison with heparin. The lengths of tail thrombosis were measured at the 24, 48, and 72h. Results: Does of 200 and 300mg/kg CMEx showed significant effects (p<0.01; p<0.001) at 24h when compared with the control group. The antithrombotic activity of 200 and 300mg/kg CMEx showed a decrease at 48 and 72h but the activity of 300mg/kg dose of CMEx was still significant (p<0.01). The activities of 50 and 100mg/kg doses of CDEx were significant (p<0.001; p<0.01) between 24 and 72h whereas 200 and 300mg/kg CDEx did not show any significance. Discussion and conclusions: CMEx and CDEx significantly inhibited the carrageenan-induced mouse tail thrombosis. Based on these results, it was concluded that CDEx and CMEx may potentially be used as therapeutic agents or complementary treatments against thrombosis.